

EVS-EN 17111:2018 INTERFLO OÜ LABORATORY Maagi 6a, 74114, Maardu Estonia Tel.+372 58098890 e-mail: norbak@norbak.ee

Quantitative carrier test for the evaluation of virucidal activity in the medical area (phase 2, step 2)

Test report no 763

1. General information

Client: Medisept Sp. z o.o., ul. Ludwika Spiessa 4, 20 270 Lublin, Poland

Date of order: 2022/11/29

2. Identification of sample

Name of the product: VIRUTON PULVER





Batch number: 220902_4

Aplication Solid product for disinfection of medical instruments

Manufacturer: Medisept Sp. z o.o

Date of delivery: 2022/11/21

Storage conditions: room temperature and darkness

Apperance of the product: Dry blend of white and blue granules and powder

Active substance and concentration 44 % Sodium percarbonate, 26 % TAED

3. Test conditions

Test period: 2022/12/05 - 2022/12/27

End of testing 2022/12/27

Product test concentrations: 0,02%, 0,5%, 1,0%, 2,0%

Exposure time: 10 min.

Test temperature: $19.5^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$

Interfering substance: for dirty conditions (bovine albumine 3,0 g/l and sheep erythrocytes 3 ml/l)

Flocculation forms with interfering substance

Neutralization of active substance: Immediate dilution, 30 min, +4°C

Diluent PBS, EMEM + 2% FBS

Stability of product in the mix with

virus and interfering substance

Test organisms: Vaccinia virus ATCC-VR-1508 strain MVA

4. Materials

1.1 Culture medium and reagents

- Eagle's Minimum Essential Medium (EMEM, Corning, REF 10-009-CVR)
- Dulbecco's modification of Eagle's Medium (DMEM, Corning, REF 10-014-CVR)
- Fetal Bovine Serum (FBS, Corning, REF 35-016-CV)
- 50% % Glutaraldehyde solution (Thermo Scientific, A10500)



- Aqua bi-distillate (Interflo OU, Estonia)
- PBS (Phosphate Buffered Saline) (Interflo OU, Estonia)
- BSA (Bovine Serum Albumin fr.V) (Roche Diagnostic GMBH)
- ShE (Defibrinated sheep erythrocytes) (BioTRADING Benelux B.V.)

1.2 Virus and cells

Strain: Modified Vaccinia virus Ankara (MVA), ATCC-VR-1508, LOT 5016818 (LGC Standards GmbH, Wesel, Germany) BHK-21 cells (C-13), ATCC-CCL-10, LOT 63226279, Kidney, Syrian Hamster (Mesocricetus auratus). Morphology – fibroblast-like (LGC Standards GmbH, Wesel, Germany)

- 1.3 Apparatus, glassware and small items of equipment
- CO2 incubator Memmert GmbH & Co. KG, ICO50 med, no D218.1233, Germany
- Agitator Vortex V-3, no 7EE0011 Biosan SIA, Latvia
- Digital pH-meter, Instrument: HI2002, SN:CO646088, Hanna, USA
- Centrifuge Centric 322A, Code: 464.000, Domel, d.o.o. BU Laboratory system, Slovenia
- Inverted microscope Motic AE2000 Series, Motic China Group, Ltd, China
- Water bath WB/OB 7-45 WBU 45 Memmert GmbH & Co. KG, Germany
- Adjustable and fixed-volume pipettes, Sartorius Lab Instruments GmbH & Co. KG Germany
- Tissue Culture Plate, 96-well, Falcon, REF 353072 Corning Incorporated, USA
- Tissue Culture flask Falcon pour culture cellulaire, REF 353108 Corning Incorporated, USA
- Tissue Culture flask Falcon pour culture cellulaire, REF 353136 Corning Incorporated, USA
- 50 mL Polypropylene Conical Tube Falcon a Corning Brand, REF 352070, Corning Science Mexico S.A. de C.V., Mexico
- Frosted Glass Carriers 15mm x60mm x1mm, one surface sandblasted, Interflo OU, Estonia



5. Methods

5.1 Preparation of test virus suspension

For the preparation of the test virus suspension according to EN 5.4.1 BHK-21 cells (C-13), ATCC-CCL-10 which were cultivated with Eagle's Minimum Essential Medium (EMEM) supplemented with L-glutamine, sodium pyruvate and 10 % fetal calf serum (FCS), were infected with a multiplicity of infection of 0,1 at 37°C. After cells showed a cytopathic effect, they were subjected to a threefold freeze/thaw procedure followed by a low speed centrifugation in order to sediment cell debris. After aliquotation of the supernatant, test virus suspension was stored at –80°C.

5.2 Preparation of disinfectant (dilutions)

The test product was evaluated as 100 % -+solution. Due to the addition of the fresh prepared hard water (5.2.2.7) heated to $35 \degree C \pm 5.0 \degree C$ and mix during the 20 min. (5 min. for dilution and 15 min for product activation) were prepared solutions for test. The test product was evaluated as 2.0 %, 1.0%, 0.5% solution and 0.02% solutions (demonstrations of non –active range).

5.3 Inoculation of the carriers

Glass carriers were placed in Petri dishes in horizontal position. Pipette 0,05ml of the mixture of test suspension and interfering substance on the inoculation square of the carrier. Inoculum were dried under an air laminar flow at 20°C in 15 min.

5.4 Infectivity assay

Infectivity was determined as endpoint titration according to EN 5.5 transferring 0.1 ml of each dilution into eight wells of a microtiter plate to 0.1 ml of freshly trypsinised cells (10 3-10 4 cells per well), beginning with the highest dilution. Microtitre plates were incubated at 37° C in a 5 % CO₂ – atmosphere. The cytopathic effect was read by using an inverted microscope after seven days. Calculation of the infective dose TCID₅₀ /ml was calculated with the method of Spearman (2) and Kärber 3) with the following formula:

$$-\log_{10} TCID$$
 50 = $Xo - 0.5 + \sum r/n$





meaning

 $X_0 = log 10$ of the lowest dilution with 100 % positive reaction

r = number of pos. determinations of lowest dilution step with 100 % positive and all higher positive dilution steps

n = number of determinations for each dilution step.

5.5 Calculation and verification of virucidal activity

The virucidal activity of the test disinfectant was evaluated by calculating the decrease in titer in comparison with the control titration without disinfectant. The difference is given as reduction factor (RF).

According to the EN 17111, a disinfectant or a disinfectant solution at a particular concentration is having virus-inactivating efficacy if the titre is reduced at least by $4 \log 10$ steps within the recommended exposure period. This corresponds to an inactivation of $\geq 99,99$ %.

5.6 Inactivation assay

Determination of virucidal activity has been carried out in accordance to EN 5.5. The test product was examined as 2,0 % 1,0%, 0,5% solutions and as 0,02% solution (demonstrations of non –active range) in water at 20°C according to EN 17111, 10 min. were chosen as contact times.

Immediately at the end of the chosen contact time, activity of the disinfectant was stopped by dilution to 10 - 8 at +4°C.

Titrations of the virus control were performed after the longest exposure time (EN 5.5.6).

Furthermore, a cell control (only addition of medium) was incorporated.

Inactivation tests were carried out in sealed test tubes in a water bath at $20^{\circ}\text{C} \pm 1.0^{\circ}\text{C}$. Aliquots were retained after appropriate exposure times, and residual infectivity was determined.

5.7 Determination of cytotoxicity

Determination of cytotoxicity was performed according to EN 5.5.3.1.



5.8 Cell sensitivity to virus

For the control of cell sensitivity to virus 0.3 parts by volume of water were mixed with 9.7 parts by volume of the lowest apparently non-cytotoxic dilution of the product. This mixture or PBS as control was added to a volume of double concentrated cell suspension. After 1 h at 37°C the cells were centrifuged and re-suspended in cell culture medium (EN 5.5.3.2b).

Finally, a comparative titration of the test virus suspension was performed on the pre-treated (disinfectant) and non-pre-treated (PBS) cells as described above.

5.9 Control of efficacy for suppression of disinfectant's activity

Furthermore, a control of efficiency for suppression of disinfectant's activity was performed according (EN 5.5.4).

5.10 Reference virus inactivation test

As reference for the test validation 50 % glutaraldehyde solution according to EN 5.5.5 was included. 5 min was chosen as contact time. In addition, cytotoxicity of glutaraldehyde test solution was determined following EN 5.5.3.1.

6. Verification of the methodology

The following criteria as mentioned in EN 5.7 were fulfilled:

- a) The titre of the test virus suspension allowed the determination of a $\geq 4 \log 10$ reduction (maximal virus reduction $\geq 6,13\pm0,00$).
- b) The difference of the logarithmic titre of the virus control minus the logarithmic titre of the test virus in the reference inactivation test (see 5.5.5) was ≥ 7.00 ($\geq 4.0 \log_{10}$) after 5 min.
- c) The test product (2,0 %) showed cytotoxicity in the 1:10 dilutions thus allowing the detection of a 4 log 10 reduction of virus titre
- d) The comparative titration on pre-treated (disinfectant) and non-pre-treated (PBS) BGM cells showed no significant difference <1 log 10 of virus titre: 7,75 (PBS) versus 7,50 (1:1000 dilutions of disinfectant) log 10 TCID50/ml.





e) The control of efficacy for suppression of disinfectant's activity (0,5%) showed no decrease in virus titer (8,50 versus 8,13 log10 TCDI50/ml).

Since all criteria according EN 5.7 fulfilled, examination with vaccinia virus according to EN 17111 is valid.

7. Results

Results for examination are shown in tables 1 to 7. Tables 1 to 6 demonstrate the raw data, whereas table 7 gives a summary of results.

The diluted test product (2,0%, 1,0%) assay) was able to inactivate vaccinia virus after 10 min. in this quantitative carrier test (Table 1,2). The reduction factor was $\geq 6,13\pm0,00$ at this time point. This corresponded to in inactivation of $\geq 99.99\%$.

The test product in 0,5 % assay was also able to inactivate vaccinia virus after 10 min. in this quantitative suspension test (Table 3). The reduction factor was $\geq 6,13\pm0,00$ at this time point.

8. Conclusion

The disinfectant for medical instruments VIRUTON PULVER tested with concentrations 2,0%, 1,0%, 0,5 % demonstrated effectiveness against Vaccinia virus after an exposure time of 10 min. under dirty conditions.

Therefore, the disinfectant for medical instruments VIRUTON PULVER (LOT 220902_4) can be declared as active against Vaccinia virus ATCC-VR-1508, thereby showing virucidal activity against enveloped viruses presented in Annex B_EN17111: 2018 guideline as follows.

0,5% 10 MIN

Tallinn, 2022/12/28

Dr. Ljudmila Šljapnikova



9. Reference

1. EN 17111:2018: Chemical disinfectants and antiseptics – Quantitative carrier test for the evaluation of virucidal activity for instruments used in the medical area – Test method and requirements (phase 2, step 2)

Annex:

Legend to the tables

- Table 1: Raw data for VIRUTON PULVER (2,0%) tested against Vaccinia virus
- Table 2: Raw data for VIRUTON PULVER (1,0%) tested against Vaccinia virus
- Table 3: Raw data for VIRUTON PULVER (0,5%) tested against Vaccinia virus
- Table 4: Raw data for VIRUTON PULVER (0,02%) tested against Vaccinia virus
- Table 5: Raw data for GLUTARLDEHYDE solution (50 %) tested against Vaccinia virus
- Table 7: Raw data for control of efficacy for suppression of disinfectant's activity (0,5 %)
- Table 8: Raw data (Vaccinia virus) for cell sensitivity (0,5 %)
- Table 9: Summary of results with VIRUTON PULVER and Vaccinia virus (a)

Legend to the Figures

Figure 1: Virus-inactivating properties of VIRUTON PULVER + ref. Glutaraldehyde (50 %)





Table 1: Raw data for VIRUTON PULVER (2,0 %) tested against Vaccinia virus at 20 °C (quantal test; 8 wells)

Product	Concentration	Interfering substance	Contact time	Dilution range (log 10)							
		substance	time	 							
				1	2	3	4	5	6	7	8
Test product	2,0%	3,0 g/L BSA +	10 min	tttt	0000	0000	0000	0000	0000	0000	0000
_		3,0 ml/L ShE		tttt	0000	0000	0000	0000	0000	0000	0000
Test product	2,0 %	3,0 g/L BSA +	n. a.	tttt	0000	0000	0000	n.d.	n.d.	n.d.	n.d.
cytotoxicity		3,0 ml/L ShE		tttt	0000	0000	0000				
Virus	n. a.	3,0 g/L BSA +	0 min	4444	4444	4444	4444	4444	4444	4444	3332
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	4444	2223
Water	n. a.	3,0 g/L BSA +	10 min	4444	4444	4444	4444	4444	4444	2222	0000
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	2332	0200

n.d. – not done

0 – no virus present

T-cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)





Table 2: Raw data for VIRUTON PULVER (1,0 %) tested against Vaccinia virus at 20 °C (quantal test; 8 wells)

Product	Concentration	Interfering substance	Contact time	Dilution range (log 10)							
		sabstance	time								
				1	2	3	4	5	6	7	8
Test product	1,0%	3,0 g/L BSA +	10 min	tttt	0000	0000	0000	0000	0000	0000	0000
_		3,0 ml/L ShE		tttt	0000	0000	0000	0000	0000	0000	0000
Test product	1,0 %	3,0 g/L BSA +	n. a.	tttt	0000	0000	0000	n.d.	n.d.	n.d.	n.d.
cytotoxicity		3,0 ml/L ShE		tttt	0000	0000	0000				
Virus	n. a.	3,0 g/L BSA +	0 min	4444	4444	4444	4444	4444	4444	4444	3332
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	4444	2223
Water	n. a.	3,0 g/L BSA +	10 min	4444	4444	4444	4444	4444	4444	2222	0000
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	2332	0200

n.d. - not done

0 – no virus present

t-cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)





Table 3: Raw data for VIRUTON PULVER (0,5 %) tested against Vaccinia virus at 20 °C (quantal test; 8 wells)

Product	Concentration	Interfering substance	Contact time	Dilution range (log 10)								
		substance	tille									
				1	2	3	4	5	6	7	8	
Test product	0,5%	3,0 g/L BSA +	10 min	tttt	0000	0000	0000	0000	0000	0000	0000	
_		3,0 ml/L ShE		tttt	0000	0000	0000	0000	0000	0000	0000	
Test product	0,5 %	3,0 g/L BSA +	n. a.	tttt	0000	0000	0000	n.d.	n.d.	n.d.	n.d.	
cytotoxicity		3,0 ml/L ShE		tttt	0000	0000	0000					
Virus	n. a.	3,0 g/L BSA +	0 min	4444	4444	4444	4444	4444	4444	4444	3332	
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	4444	2223	
Water	n. a.	3,0 g/L BSA +	10 min	4444	4444	4444	4444	4444	4444	2222	0000	
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	2332	0200	

n.d. – not done

0 – no virus present

T-cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)





Table 4: Raw data for VIRUTON PULVER (0,02 %) tested against Vaccinia virus at 20 °C (quantal test; 8 wells)

Product	Concentration	Interfering substance	Contact time	Dilution range (log 10)								
							,	_	_	_		
				1	2	3	4	5	6	7	8	
Test product	0,02%	3,0 g/L BSA +	10 min	tttt	4444	4444	2222	0000	0000	0000	0000	
		3,0 ml/L ShE		tttt	4444	4444	2220	0000	0000	0000	0000	
Test product	0,02 %	3,0 g/L BSA +	n. a.	tttt	0000	0000	0000	n.d.	n.d.	n.d.	n.d.	
cytotoxicity		3,0 ml/L ShE		tttt	0000	0000	0000					
Virus	n.a.	3,0 g/L BSA +	0 min	4444	4444	4444	4444	4444	4444	4444	3332	
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	4444	2223	
Water	n. a.	3,0 g/L BSA +	10 min	4444	4444	4444	4444	4444	4444	2222	0000	
control		3,0 ml/L ShE		4444	4444	4444	4444	4444	4444	2332	0200	

n.d. – not done

0 – no virus present

T-cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)





Table 5: Raw data for Glutaraldehyde solution (50,0 %) tested against Vaccinia virus at 20 °C (quantal test; 8 wells)

Product	Concentration	Interfering substance	Contact time	Dilution range (log 10)								
				1	2	3	4	5	6	7	8	
Glutaraldehyde	50,0 %	PBS	5 min	tttt	0000	0000	0000	0000	0000	0000	0000	
	(m/V)			tttt	0000	0000	0000	0000	0000	0000	0000	
Glutaraldehyde	50,0 %	PBS	n.a.	tttt	0000	0000	n.d.	n.d.	n.d.	n.d.	n.d.	
cytotoxicity	(m/V)			tttt	0000	0000						
Virus control	n. a.	PBS	5 min	4444	4444	4444	4444	4444	4444	4444	2332	
				4444	4444	4444	4444	4444	4444	4444	2323	

n.d. – not done

0 – no virus present

T-cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)





Table 6: Raw data for control efficacy for suppression of disinfectant activity 0,5 %,

Product	Concentration	Interfering substance		Dilution range (log 10)									
			1	2	3	4	5	6	7	8			
VIRUTON	0,5 %	3,0 g/L BSA +	tttt	4444	4444	3344	3333	3223	2222	2200			
PULVER		3,0 ml/L ShE	tttt	4444	4444	4444	3333	3222	2222	0222			
Virus	n. a.	3,0 g/L BSA +	4444	4444	4444	4444	4444	4444	4444	2222			
control		3,0 ml/L ShE	4444	4444	4444	4444	4444	4444	4444	2222			

n.d. – not done

0 – no virus present

t – cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)



Table 7: Raw data (vaccinia virus) for cell sensitivity (0,5%)

Product	Dilution	Interfering substance	Dilution range (log 10)								
			1	2	3	4	5	6	7	8	
PBS	-	-	4444	4444	4444	4444	4444	4444	4444	2333	
			4444	4444	4444	4444	4444	4444	4444	2333	
VIRUTON	1:1000	3,0 g/L BSA +	4444	4444	4444	4444	4444	4444	4444	2222	
PULVER		3,0 ml/L ShE	4444	4444	4444	4444	4444	4444	4444	2222	

n.d. – not done

0 – no virus present

t-cytotoxic

1 to 4 – virus present (degree of CPE in 8 cells units) (wells of microtiter plates)





Table 8: Summary of results of activity of the product VIRUTON PULVER with Vaccinia virus, Ankara, MVA, ATCC VR – 1508

						log10 TCII	log10 TCID50 / ml			
Assay	Interfering	Concentration	Cytotoxicity			after	•••		the confidence	
	substance		level	0 min	5 min	10 min	30 min	60 min	interval of 95 %	
			\log_{10}							
	3,0 g/L BSA +	2,0 %	1,5			≤1,50			≥6,13±0,00	
Test product	3,0 ml/L ShE	1,0 %	1,5			≤1,50			≥6,13±0,00	
		0,5 %	1,5			≤1,50			≥6,13±0,00	
		0,02 %	1,5			4,38±0,13			3,25±0,25	
Water control	3,0 g/L BSA +	0%	n.a.			7,63±0,13				
	3,0 ml/L ShE									
Virus control	3,0 g/L BSA +	n.a.	n.a.	8,50±0,00			8,50		n.a.	
	3,0 ml/L ShE									
Glutaraldehyde	PBS	50 % (w:v)	1,5		≤1,50				≥7,00	
Virus control for	PBS	n.a.	n.a.		8,50				n.a.	
Glutaraldehyde										
Suppression of	3,0 g/L BSA +	0,5 %	1,5				8,13		n.a.	
disinfectant activity	3,0 ml/L ShE									
Cell sensitivity	PBS	n.a.	n.a.					7,75	n.a.	
control										
PBS										
Cell sensitivity	3,0 g/L BSA +	1:1000	n.a.					7,50	n.a.	
control test product	3,0 ml/L ShE									



Figure 1



